FDA approves single-dose prefilled syringes for Wegovy

The FDA has cleared a new way to take Wegovy (semaglutide): a prefilled glass syringe with an integrated needle, offered in five strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg — according to the drug's current prescribing information ^[2]. This adds a third delivery option alongside the once-weekly injectable pen and the once-daily tablet that Novo Nordisk already sells under the Wegovy name ^[1].

The prescribing information lists the single-dose syringe as a distinct dosage form from the single-dose pen and the multi-dose FlexTouch pen, which delivers four 2.4 mg doses from one device ^[2]. The standard dosing plan calls for starting at 0.25 mg once weekly for four weeks, then increasing the dose roughly every four weeks until reaching the usual maintenance dose of 2.4 mg weekly, following a schedule set out in the label ^[2]. This titration schedule applies to Wegovy injection generally and is not described differently for the syringe form in the available sources.

As of the materials reviewed, Novo Nordisk's consumer-facing Wegovy FAQ page describes the pen as a "prefilled, single-use pen" with a hidden needle and preset dose, and it explains storage rules — refrigerated between 36°F and 46°F, or at room temperature for up to 28 days once removed from the fridge — along with instructions for missed doses ^[1]. That page does not mention the new syringe option or say whether it is stocked at retail pharmacies ^[1]. Whether the syringe has reached pharmacy shelves, and on what timeline, is not established in the sources available for this story.

Why it matters for patients

A prefilled syringe with a visible, integrated needle is a different physical device than the hidden-needle pen patients have used since Wegovy launched in 2021 ^[1]. People who currently use the pen and are used to its design may need updated instructions if they are prescribed the syringe instead, since the label directs patients to follow the specific Instructions for Use and guidance from a health professional ^[1].

The boxed warning and safety information that apply to Wegovy injection generally also apply regardless of which device delivers the dose. The label carries a boxed warning about thyroid C-cell tumors seen in rodent studies, and it is unknown whether this risk applies to humans; the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[2]. Other listed precautions include pancreatitis, gallbladder disease, low blood sugar when combined with insulin or certain diabetes drugs, kidney injury linked to fluid loss, severe gastrointestinal reactions, allergic reactions, and increased heart rate ^[2]. Common side effects across Wegovy forms include nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, and hair loss ^[1][2].

For people deciding between Wegovy formats, the sources do not describe cost or insurance differences tied to the syringe specifically, nor do they compare its convenience to the pen or tablet beyond noting it is a separate FDA-listed dosage form ^[2].

What happens next

The sources do not give a date for when the prefilled syringe will be stocked at U.S. pharmacies. Novo Nordisk's patient-facing FAQ page, as reviewed, still describes only the pen and pill as ways to take Wegovy, without addressing the syringe's rollout ^[1]. Patients with questions about availability or which device is right for them are directed in the label to talk with their prescriber ^[1][2].